Iradimed CorpIRMD
Price$85.30Intrinsic value$70.3718% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $70.37median of 6 methods · middle span $44-$75based on filings through 30 Jun 2026
Market Price $85.30Price as of 1 Oct 2026
Margin of Safety -17.5%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 12.0% (near-term consensus, capped) · years 2–5: 12.0%/yr (balance of the path).12.0% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 612.0%Yr 712.0%Yr 812.0%Yr 912.0%Yr 1012.0%
12.0% → 12.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1111.1%Yr 1210.2%Yr 139.3%Yr 148.4%Yr 157.5%Yr 166.6%Yr 175.7%Yr 184.8%Yr 193.9%Yr 203.0%
12.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)18.9%
Discount rate (cost of equity) 9.1%
Volatility vs market (adjusted beta)0.93

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetIradimed CorpIRMDHealth Care
Valuation
P/E47.7×
P/S12.3×
P/B10.5×
EV / Revenue11.6×
EV / EBITDA38.8×
Profitability
Gross margin77.0%
Operating margin31.2%
Net margin26.7%
FCF margin29.1%
Returns
ROE22.7%
ROA20.1%
ROIC54.0%
Growth
Revenue growth (YoY)17.9%
5-yr fwd EPS growth12.0%
Financial strength
Debt / Equity0.00×
Current ratio9.46×
Altman Z-Score53.4
Interest coverage—
Dividend yield1.0%

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.